Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

A drug used at the maximum tolerated dose can exert a strong selective pressure on cancer cells leading to resistance. In this study, the authors demonstrate the efficacy of using low dose of multiple drugs for preventing and treating resistance to EGFR tyrosine kinase inhibitors in NSCLC cells.

Enregistré dans:
Détails bibliographiques
Auteurs principaux: João M. Fernandes Neto, Ernest Nadal, Evert Bosdriesz, Salo N. Ooft, Lourdes Farre, Chelsea McLean, Sjoerd Klarenbeek, Anouk Jurgens, Hannes Hagen, Liqin Wang, Enriqueta Felip, Alex Martinez-Marti, August Vidal, Emile Voest, Lodewyk F. A. Wessels, Olaf van Tellingen, Alberto Villanueva, René Bernards
Format: article
Langue:EN
Publié: Nature Portfolio 2020
Sujets:
Science
Q
Accès en ligne:https://doaj.org/article/fa274e19e6774a2dbd7ad05e9103dbab
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Documents similaires